STK4141V Amplifier Hybrid Transistors


  1. Home
  2. STK4141V Amplifier Hybrid
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
STK4141V Hybrid Amplifier
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Model:

2STK4141V

Brand:

Unbranded

MPN:

2STK4141V

UPC:

Does not apply

published on tue nov 09 2021

STK4141V Amplifier Hybrid Transistors

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

STK4141V Amplifier Hybrid Transistors

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS